Category Human tissue array
   Cat. No. CS
   Product description Liver cancer
   Data sheet CS1.pdf
CS1.xls
   
  general_information
   No. of samples 59
   Text
Current version: CS1 
Liver cancer: 59 cores

Price : 5 slide for 600 $

CS1  Human, liver cancer
               
  Age Sex Organ Diagnosis TNM Stage No. of 
CSN1#
1 53 F skin metastatic HCC TxNxM1 ⅣB .
2 57 M liver HCC T3N0M0 ⅢA 104
3 41 M liver HCC T3N0M0 ⅢA .
4 45 M skin metastatic HCC TxNxM1 ⅣB .
5 54 F chest wall metastatic HCC TxNxM1 ⅣB .
6 40 M lumbar vertebra metastatic HCC TxNxM1 ⅣB .
7 52 M liver HCC T3N0M0 ⅢA 112
8 43 M bile duct HCC T4NxM0 ⅣA .
9 51 M colon metastatic HCC TxNxM1 ⅣB .
10 49 M bile duct HCC T4NxM0 ⅣA .
11 56 M liver HCC T3N0M0 ⅢA .
12 56 F lung metastatic HCC TxNxM1 ⅣB .
13 40 M lymph node metastatic HCC T3N1M0 ⅢB .
14 37 M liver HCC T4NxM1 ⅣB 131
15 75 M liver HCC T1N0M0 132
16 37 M neck metastatic HCC TxNxM1 ⅣB .
17 32 M liver HCC T3N0M0 ⅢA 133
18 50 M femur metastatic HCC TxNxM1 ⅣB .
19 57 M liver HCC T3N0M0 ⅢA 134
20 62 M lung metastatic HCC TxNxM1 ⅣA .
21 61 M lung metastatic HCC TxNxM1 ⅣB .
22 65 M liver moderately differentiated HCC T2N0M0 135
23 52 M liver moderately differentiated HCC T1N0M0 136
24 65 M liver poorly differentiated HCC T2N0M0 137
25 72 M liver well & poorly differentiated HCC T2N0M0 138
26 58 F liver well differentiated HCC T2N0M0 139
27 52 M liver well differentiated HCC T2N0M0 140
28 40 M liver moderately differentiated HCC T2N0M0 141
29 53 F liver moderately differentiated HCC T3N0M0 ⅢA 142
30 67 M liver moderately differentiated HCC T2N0M0 143
31 58 F liver moderately differentiated HCC T2N0M0 .
32 20 M liver well differentiated HCC T4N0M0 ⅣA .
33 48 M liver moderately differentiated HCC T2N0M0 .
34 47 M liver HCC T1N0M0 144
35 35 M omentum metastatic HCC TxNxM1 ⅣB .
36 69 F liver moderately differentiated HCC T2N0M0 .
37 65 M liver well differentiated HCC T2N0M0 145
38 63 F liver moderately differentiated HCC T2N0M0 146
39 60 F liver poorly differentiated HCC T2N0M0 147
40 65 F liver moderately differentiated HCC T3N0M0 ⅢA 148
41 69 F liver poorly differentiated HCC T3N0M0 ⅢA .
42 66 F liver well differentiated HCC T2N0M0 149
43 65 F liver moderately differentiated HCC T1N0M0 150
44 64 M liver poorly differentiated HCC T3N0M0 ⅢA .
45 59 M liver moderately differentiated HCC T3N0M0 ⅢA .
46 64 M liver moderately differentiated HCC T2N0M0 151
47 51 M liver moderately differentiated HCC T4N0M0 ⅢA 152
48 65 F liver moderately differentiated HCC T2N0M0 153
49 60 M adrenal gland metastatic HCC TxNxM1 ⅣB .
50 44 M liver moderately differentiated HCC T1N0M0 .
51 41 M liver moderately differentiated HCC T2N0M0 .
52 51 M liver HCC T2N0M0 154
53 49 M liver well differentiated HCC T4N0M0 ⅣA 155
54 57 F liver well differentiated HCC T2N0M0 156
55 57 M liver moderately differentiated HCC T3N0M0 ⅢA 157
56 43 M liver  moderately differentiated HCC T2N0M0 .
57 50 M liver poorly differentiated HCC T2N0M0 158
58 43 M liver moderately differentiated HCC T2N0M0 159
59 60 F liver poorly differentiated HCC T4N0M0 ⅣA 160
60 carbon particle
               
HCC : hepatocellular carcinoma          
TNM and stage classification : liver cancer (AJCC 5th Edition)      

General Information of the Tissue Array Slide :

Applications

  • Immunohistochemistry
  • In situ hybridization, RNA or DNA
  • Fluorescent in situ hybridization (FISH)
  • In situ PCR, RNA or DNA
  • TUNEL for apoptosis (Recommended procedures in www.tissue-array.com -> protocol)

Storage and stability

  • Individual slide is paraffin-coated and put in an air-tight pack with inert gas.
  • Tissue array slides are shipped in room temperature.
  • If the slides are stored in 4 degree, they are good up to one year.

How processed

  • Tissues were initially fixed with formalin except for some of the animal tissues.
  • Then, dehydrated with gradient ethanol; typically 1 hour each progressive steps; 70%, 90%, 95%, 99%, 100% x 3 times.
  • Cleared by xylene, three changes for 1 hour each.
  • Infiltrated with 60°C paraffin, three changes for 1 hour each
  • Microtoming in 4 µm thickness and put on silane coating slide from Muto Pure Chemicals (Japan)

Before use

  • Dry slides for 1 hour in a oven at 60 degree.
  • Dewax slides in xylene for 4 minutes x 5 times
  • Hydrate slides in 100%, 95% and 75% ethanol for 3 minutes x 2 times each.
  • Immerse slides in tap water for 5 minutes

Slide orientation

  • In most of the slides with 59 or 60 cores, the orientation is as below unless indicated otherwise. #60 location is usually filled with carbon for orientation.

Shaded area

1 2 3 4 5 6 7 8 9 10
11 12 13 14 15 16 17 18 19 20
21 22 23 24 25 26 27 28 29 30
31 32 33 34 35 36 37 38 39 40
41 42 43 44 45 46 47 48 49 50
51 52 53 54 55 56 57 58 59 60
Category Human tissue array
   Cat. No. CR
   Product description Esophagus cancer
   Data sheet CR1
CR1
   
  general_information
   No. of samples 60
   Text
Current version: CR1 
Esophagus cancer: 60 cores

Price : 5 slide for 600 $

CR1  Human, esophageal cancer
             
  Age Sex Organ Diagnosis TNM Stage
1 58 M esophagus basaloid carcinoma T3N0M0 ⅡA
2 54 M esophagus squamous cell carcinoma, moderately differentiated T2N1M0 ⅡB
3 57 M esophagus squamous cell carcinoma, poorly differentiated T3N1M0
4 75 M esophagus squamous cell carcinoma T3N1M0
5 46 M esophagus squamous cell carcinoma, well differentiated T3N1M0
6 58 M esophagus squamous cell carcinoma, moderately differentiated T3N1M0
7 70 M esophagus squamous cell carcinoma, moderately differentiated T3N1M0
8 66 M esophagus squamous cell carcinoma, moderately differentiated T3N0M0 ⅡA
9 53 M esophagus small cell carcinoma T2N1M0 ⅡB
10 67 M esophagus squamous cell carcinoma, moderately differentiated T3N0M0 ⅡA
11 60 F esophagus squamous cell carcinoma, moderately differentiated T3N0M0 ⅡA
12 69 M esophagus squamous cell carcinoma, moderately differentiated T3N0M0 ⅡA
13 62 M esophagus squamous cell carcinoma, moderately differentiated T3N0M0 ⅡA
14 57 M esophagus squamous cell carcinoma, moderately differentiated T3N1M0
15 62 M esophagus squamous cell carcinoma, well differentiated T3N0M0 ⅡA
16 36 F esophagus adenocarcinoma, well differentiated T1N0M0
17 60 M esophagus squamous cell carcinoma, well differentiated T3N0M0 ⅡA
18 50 M esophagus squamous cell carcinoma, moderately differentiated T3N0M0 ⅡA
19 60 F esophagus squamous cell carcinoma, moderately differentiated T3N1M0
20 57 M esophagus squamous cell carcinoma, moderately differentiated T3N1M0
21 58 M esophagus squamous cell carcinoma, well differentiated T3N1M0
22 74 M esophagus squamous cell carcinoma, moderately differentiated T3N0M0 ⅡA
23 56 F esophagus squamous cell carcinoma, poorly differentiated T3N1M0
24 43 M esophagus squamous cell carcinoma, well differentiated T3N1M0
25 69 M esophagus invasive squamous cell ca., moderately differentiated T3N1M0
26 58 M esophagus squamous cell carcinoma, poorly differentiated T3N1Mx 0
27 62 M esophagus squamous cell carcinoma, well differentiated T4N0M0
28 63 M esophagus  adenosquamous carcinoma T3N1M0
29 56 M esophagus squamous cell carcinoma, well differentiated T4N1M0
30 59 M esophagus squamous cell carcinoma, moderately differentiated T3N1M0
31 50 M esophagus squamous cell carcinoma, well differentiated T3N1M0
32 52 M esophagus squamous cell carcinoma, well differentiated T2N1M0 ⅡB
33 58 M esophagus squamous cell carcinoma, moderately differentiated T3N1M0
34 64 F esophagus squamous cell carcinoma, moderately differentiated T3N1M0
35 60 M esophagus squamous cell carcinoma, moderately differentiated T3N1M0
36 64 M esophagus squamous cell carcinoma, well differentiated T3N1M0
37 52 M esophagus squamous cell carcinoma, well differentiated T3N1M0
38 45 M esophagus adenosquamous carcinoma T2N0M0 ⅠB
39 46 M esophagus squamous cell carcinoma, well differentiated T3N0M0 ⅡA
40 66 M esophagus squamous cell carcinoma, moderately differentiated T3N0M0 ⅡA
41 69 M esophagus squamous cell carcinoma, moderately differentiated T3N1M0
42 60 M esophagus squamous cell carcinoma, well differentiated T3N1M0
43 62 M esophagus squamous cell carcinoma, well differentiated T3N1M1b ⅣB
44 52 M esophagus squamous cell carcinoma, poorly differentiated T3N0M0
45 59 M esophagus squamous cell carcinoma, moderately differentiated T3N1M0
46 67 M esophagus squamous cell carcinoma, moderately differentiated T3N1Mx 0
47 65 M esophagus adenosquamous cell carcinoma T4N0M0
48 51 M esophagus adenosquamous cell ca., moderately differentiated T3N0M0 ⅡA
49 47 M esophagus squamous cell carcinoma, well differentiated T3N1M0
50 42 M esophagus squamous cell carcinoma, moderately differentiated T3N1M1a ⅣA
51 66 M esophagus squamous cell carcinoma, poorly differentiated T3N1M0
52 53 M esophagus adenocarcinoma, moderately differentiated T3N1M0
53 59 M esophagus squamous cell carcinoma, well differentiated T3N1M0
54 59 M esophagus squamous cell carcinoma, moderately differentiated T3N1M0
55 50 M esophagus squamous cell carcinoma, moderately differentiated T3N1M0
56 42 M esophagus squamous cell carcinoma, moderately differentiated T3N0M0 ⅡA
57 69 M esophagus adenocarcinoma, poorly differentiated T3N1Mx 0
58 54 M esophagus squamous cell carcinoma, moderately differentiated T3N0M0 ⅡA
59 70 M esophagus squamous cell carcinoma, moderately differentiated T2N1M0 ⅡB
60 68 M esophagus squamous cell carcinoma, well differentiated T3N1MX 0
             
TNM and stage classification : Esophagus cancer (AJCC 5th Edition)    

General Information of the Tissue Array Slide :

Applications

  • Immunohistochemistry
  • In situ hybridization, RNA or DNA
  • Fluorescent in situ hybridization (FISH)
  • In situ PCR, RNA or DNA
  • TUNEL for apoptosis (Recommended procedures in www.tissue-array.com -> protocol)

Storage and stability

  • Individual slide is paraffin-coated and put in an air-tight pack with inert gas.
  • Tissue array slides are shipped in room temperature.
  • If the slides are stored in 4 degree, they are good up to one year.

How processed

  • Tissues were initially fixed with formalin except for some of the animal tissues.
  • Then, dehydrated with gradient ethanol; typically 1 hour each progressive steps; 70%, 90%, 95%, 99%, 100% x 3 times.
  • Cleared by xylene, three changes for 1 hour each.
  • Infiltrated with 60°C paraffin, three changes for 1 hour each
  • Microtoming in 4 µm thickness and put on silane coating slide from Muto Pure Chemicals (Japan)

Before use

  • Dry slides for 1 hour in a oven at 60 degree.
  • Dewax slides in xylene for 4 minutes x 5 times
  • Hydrate slides in 100%, 95% and 75% ethanol for 3 minutes x 2 times each.
  • Immerse slides in tap water for 5 minutes

Slide orientation

  • In most of the slides with 59 or 60 cores, the orientation is as below unless indicated otherwise. #60 location is usually filled with carbon for orientation.

Shaded area

1 2 3 4 5 6 7 8 9 10
11 12 13 14 15 16 17 18 19 20
21 22 23 24 25 26 27 28 29 30
31 32 33 34 35 36 37 38 39 40
41 42 43 44 45 46 47 48 49 50
51 52 53 54 55 56 57 58 59 60
Category Human tissue array
   Cat. No. CQN
   Product description Normal stomach tissue
   Data sheet CQN1
CQN1
  general_information
   No. of samples 59
   Text
Current version: CQN1 
Normal sotmach: 59 cores

Price : 5 slide for 600 $

CQN1  Normal tissue of CQ1
           
No Age Sex Organ Histology No. of CQ1#
101 40 M Gastric mucosa . 1
102 43 F Gastric mucosa . 2
103 61 F Gastric mucosa . 3
104 45 M Gastric mucosa . 4
105 67 F Gastric mucosa . 5
106 53 M Gastric mucosa . 6
107 67 M Gastric mucosa . 7
108 72 M Gastric mucosa . 8
109 61 M Gastric mucosa . 9
110 65 M Gastric mucosa . 10
111 70 M Gastric mucosa . 11
112 62 M Gastric mucosa . 12
113 62 F Gastric mucosa . 11
114 52 M Gastric mucosa . 14
115 60 M Gastric mucosa . 15
116 66 M Gastric mucosa . 16
117 41 M Gastric mucosa . 17
118 60 F Gastric mucosa . 18
119 59 M Gastric mucosa . 19
120 62 M Gastric mucosa . 20
121 49 M Gastric mucosa . 21
122 64 M Gastric mucosa . 22
123 55 M Gastric mucosa . 23
124 56 F Gastric mucosa . 24
125 48 M Gastric mucosa . 25
126 65 F Gastric mucosa . 26
127 63 M Gastric mucosa . 27
128 60 M Gastric mucosa . 28
129 42 M Gastric mucosa . 29
130 55 M Gastric mucosa . 30
131 58 M Gastric mucosa . 31
132 72 F Gastric mucosa . 32
133 53 M Gastric mucosa . 33
134 46 M Gastric mucosa . 34
135 64 M Gastric mucosa . 35
136 65 M Gastric mucosa . 36
137 45 F Gastric mucosa . 37
138 58 F Gastric mucosa . 38
139 68 F Gastric mucosa . 39
140 66 M Gastric mucosa . 40
141 63 M Gastric mucosa . 41
142 52 F Gastric mucosa . 42
143 35 F Gastric mucosa . 43
144 44 F Gastric mucosa . 44
145 55 M Gastric mucosa . 45
146 40 M Gastric mucosa . 46
147 66 M Gastric mucosa . 47
148 65 F Gastric mucosa . 48
149 62 F Gastric mucosa . 49
150 60 F Gastric mucosa . 50
151 70 F Gastric mucosa . 51
152 52 M Gastric mucosa . 52
153 40 M Gastric mucosa . 53
154 34 F Gastric mucosa . 54
155 60 M Gastric mucosa . 55
156 68 M Gastric mucosa . 56
157 52 M Gastric mucosa . 57
158 62 M Gastric mucosa . 58
159 60 M Gastric mucosa . 59
160 . . Carbon . .
           
#: The cancer tissue in CQ1 array of this column is from the identical patient.  

General Information of the Tissue Array Slide :

Applications

  • Immunohistochemistry
  • In situ hybridization, RNA or DNA
  • Fluorescent in situ hybridization (FISH)
  • In situ PCR, RNA or DNA
  • TUNEL for apoptosis (Recommended procedures in www.tissue-array.com -> protocol)

Storage and stability

  • Individual slide is paraffin-coated and put in an air-tight pack with inert gas.
  • Tissue array slides are shipped in room temperature.
  • If the slides are stored in 4 degree, they are good up to one year.

How processed

  • Tissues were initially fixed with formalin except for some of the animal tissues.
  • Then, dehydrated with gradient ethanol; typically 1 hour each progressive steps; 70%, 90%, 95%, 99%, 100% x 3 times.
  • Cleared by xylene, three changes for 1 hour each.
  • Infiltrated with 60°C paraffin, three changes for 1 hour each
  • Microtoming in 4 µm thickness and put on silane coating slide from Muto Pure Chemicals (Japan)

Before use

  • Dry slides for 1 hour in a oven at 60 degree.
  • Dewax slides in xylene for 4 minutes x 5 times
  • Hydrate slides in 100%, 95% and 75% ethanol for 3 minutes x 2 times each.
  • Immerse slides in tap water for 5 minutes

Slide orientation

  • In most of the slides with 59 or 60 cores, the orientation is as below unless indicated otherwise. #60 location is usually filled with carbon for orientation.

Shaded area

1 2 3 4 5 6 7 8 9 10
11 12 13 14 15 16 17 18 19 20
21 22 23 24 25 26 27 28 29 30
31 32 33 34 35 36 37 38 39 40
41 42 43 44 45 46 47 48 49 50
51 52 53 54 55 56 57 58 59 60
Category Human tissue array
   Cat. No. CQ
   Product description Stomach cancer
   Data sheet CQ1.pdf
CQ1.xls
   
  general_information
   No. of samples 59
   Text
Current version: CQ1 
Stomach cancer: 59 cores

Price : 5 slide for 600 $

CQ1 human, stomach cancer
                 
No Age Sex AGC vs. EGC* TNM Stage Histology** Lauren*** No. of 
CQN1 #
1 40 M A T3N2M1 P/D D 101
2 43 F A T3N0M0 P/D D 102
3 61 F A T2N2M0 ⅢA M/D I 103
4 45 F A T2N2Mx 0 SRC D 104
5 67 M A T2N1M0 P/D D 105
6 53 F A T2N2M0 ⅢA P/D D 106
7 67 M A T3N3M0 M/D I 107
8 72 M A T2N2Mx 0 P/D D 108
9 61 M A T2N1M0 mucinous I 109
10 65 M A T4N0M0 ⅢA P/D D 110
11 70 M A T3N1M0 ⅢA M/D I 111
12 62 M A T2N1M0 W/D I 112
13 62 F A T2N1M0 SRC D 113
14 52 M A T2N0M0 ⅠB papillary I 114
15 60 M A T2N2M1 P/D D 115
16 66 M A T3N3M0 P/D D 116
17 41 M A T2N2M0 ⅢA SRC D 117
18 60 F A T2N2M0 ⅢA P/D D 118
19 59 M A T3N3M0 P/D D 119
20 62 M A T2N3M0 P/D D 120
21 49 M A T4N3M0 P/D D 121
22 64 M A T2N1M0 mucinous I 122
23 55 M A T3N3M0 undiffentiated D 123
24 56 F A T2N1M0 P/D D 124
25 48 M A T2N1M0 P/D D 125
26 65 F A T4N2M0 mucinous D 126
27 63 M A T2N1M0 W/D I 127
28 60 M A T2N0M0 ⅠB W/D I 128
29 42 M A T2N1M0 SRC D 129
30 55 M A T2N2M0 ⅢA mucinous 0 130
31 58 M A T2N3M0 M/D I 131
32 72 F E T1N1M0 ⅠB M/D I 132
33 53 M A T2N0M0 ⅠB P/D D 133
34 46 M A T4N0M0 ⅢA P/D D 134
35 64 M A T2N1M0 M/D I 135
36 65 M A T2N1M0 P/D D 136
37 45 F A T2N1M0 P/D D 137
38 58 F A T2N0M0 ⅠB W/D I 138
39 68 F A T3N2M1 P/D D 139
40 66 M A T3N2M0 ⅢB P/D D 140
41 63 M A T2N0M0 ⅠB P/D D 141
42 52 F A T2N1M0 M/D I 142
43 35 F E T1N0M0 ⅠA P/D D 143
44 44 F E T1N0M0 ⅠA W/D I 144
45 55 M E T1N0M0 ⅠA W/D I 145
46 40 M E T1N0M0 ⅠA SRC D 146
47 66 M E T1N0M0 ⅠA M/D I 147
48 65 F E T1N0M0 ⅠA M/D I 148
49 62 F E T1N0M0 ⅠA P/D D 149
50 60 F E T1N0M0 ⅠA M/D I 150
51 70 F E T1N1M0 ⅠB M/D I 151
52 52 M E T1N0M0 ⅠA W/D I 152
53 40 M E T1N1M0 ⅠB SRC D 153
54 34 F E T1N1M0 ⅠB SRC D 154
55 60 M E T1N0M0 ⅠA W/D I 155
56 68 M E T1N1M0 ⅠB W/D I 156
57 52 M E T2N0M0 ⅠB W/D I 157
58 62 M E T1N0M0 ⅠA SRC D 158
59 60 M E T1N0M0 ⅠA W/D I 159
60                                    carbon              
                 
*A, Advanced carcinoma; E, Early carcinoma          
** WHO classification  W/D, well differentiated; M/D, moderately differentiated;  P/D, poorly differentiated    
                                  SRC, Signet ring cell carcinoma          
*** Lauren classification   D, diffuse; I, intestinal           
# The normal tissue in CQN1 array of this column is from the identical patient.        
TNM and stage classification : stomach cancer (AJCC 5th Edition)        

General Information of the Tissue Array Slide :

Applications

  • Immunohistochemistry
  • In situ hybridization, RNA or DNA
  • Fluorescent in situ hybridization (FISH)
  • In situ PCR, RNA or DNA
  • TUNEL for apoptosis (Recommended procedures in www.tissue-array.com -> protocol)

Storage and stability

  • Individual slide is paraffin-coated and put in an air-tight pack with inert gas.
  • Tissue array slides are shipped in room temperature.
  • If the slides are stored in 4 degree, they are good up to one year.

How processed

  • Tissues were initially fixed with formalin except for some of the animal tissues.
  • Then, dehydrated with gradient ethanol; typically 1 hour each progressive steps; 70%, 90%, 95%, 99%, 100% x 3 times.
  • Cleared by xylene, three changes for 1 hour each.
  • Infiltrated with 60°C paraffin, three changes for 1 hour each
  • Microtoming in 4 µm thickness and put on silane coating slide from Muto Pure Chemicals (Japan)

Before use

  • Dry slides for 1 hour in a oven at 60 degree.
  • Dewax slides in xylene for 4 minutes x 5 times
  • Hydrate slides in 100%, 95% and 75% ethanol for 3 minutes x 2 times each.
  • Immerse slides in tap water for 5 minutes

Slide orientation

  • In most of the slides with 59 or 60 cores, the orientation is as below unless indicated otherwise. #60 location is usually filled with carbon for orientation.

Shaded area

1 2 3 4 5 6 7 8 9 10
11 12 13 14 15 16 17 18 19 20
21 22 23 24 25 26 27 28 29 30
31 32 33 34 35 36 37 38 39 40
41 42 43 44 45 46 47 48 49 50
51 52 53 54 55 56 57 58 59 60
 Category Human tissue array
   Cat. No. CL
   Product description Kidney cancer
   Data sheet CL1
CL1
   
  general_information
   No. of samples 59
   Text
Current version: CL1 
Kidney cancer: 50 cores 
Normal kidney: 9 cores

Price : 5 slide for 600 $

CL1 Human, kidney cancer
                   
  Age Sex Diagnosis Size(cm) Capsule Vein Other N M
1 52 F RCC, granular cell types 12 + - - NX M0
2 60 F RCC, clear cell type 6 + + - N0 M1
3 42 M RCC, clear cell type 9 + + - NX M0
4 59 M RCC, clear cell type 7,5 + - - NX M0
5 67 F RCC, clear cell and granular cell type 8 + - - NX M0
6 65 M RCC, granular and clear cell type 11 + - - NX M0
7 59 M RCC, clear cell and granular cell type 7 + + - NX M0
8 56 M RCC, clear and pseudosarcomatous type 7 + - - NX M1*
9 42 F RCC, clear cell type 10 - + - NX M0
10 50 M RCC, clear cell type 3,5 - - - N0 M0
11 52 M RCC, clear cell type 4 - - - N0 M0
12 68 F RCC, clear cell type 6 + + - N0 M0
13 60 F RCC, clear cell type 5 - + - N0 M0
14 69 F RCC, clear cell type 7,5 + - - NX M
15 54 M RCC, clear cell type 7 + - - NX M0
16 43 F RCC, clear cell type 4 + - - N0 M0
17 53 M RCC, clear cell type 5,5 - - +* NX M1**
18 . M RCC, clear cell type 3,5 - + - N0 M0
19 . . RCC, collecting duct type 4 + - - NX M0
20 40 M RCC, clear cell type 2,2 - - - NX M0
21 52 M RCC, clear cell type 6 + - - NX M0
22 63 F RCC, clear cell and granular cell type 7,5 + - - NX M0
23 64 M RCC, clear cell type 5,4 + - - NX M0
24 37 M RCC, collecting duct type 10,5 - - - N0 M0
25 65 M RCC, papillary type 5 - - - NX M0
26 74 M RCC, clear type 17 - + - N0 M0
27 67 M RCC, clear cell type 9 + + +*    NX M0
28 50 M RCC 9 - - - N0 M0
29 74 M RCC, clear cell type 17 - + - N0 M0
30 62 M RCC, clear granular cell 7 + + - NX M0
31 64 M RCC, papillary type 4 - - - NX M0
32 45 M RCC, clear cell type 6,5 - - - N0 M0
33 62 M RCC 10 + - - N1 M0
34 53 M RCC, clear cell type 4,5 + - - NX M0 
35 64 M RCC, clear cell type 6 - - - NX M0
36 72 M RCC, clear cell type 1,5 - - - NX M0
37 62 F RCC, clear cell type 11 - - +* NX M0
38 56 M RCC, clear cell type 4 + + - NX M0
39 58 M RCC 8,5 - - - NX M0
40 57 M RCC, clear cell and granular cell type 10 + - - N0 M0
41 64 F Transitional cell carcinoma, pelvis . . . . . .
42 43 F RCC, clear cell type 6 - - - NX M0
43 52 F RCC, granular cell type 7 - - - NX M0
44 64 M RCC, granular cell type 10 - + +* NX M0
45 57 M RCC, clear cell type 4,5 + - - NX M0
46 59 M RCC, clear cell type and granular cell type 8 + - - NX M0
47 47 M RCC, clear cell type 4 + - - NX M0
48 77 M RCC, clear cell type 2,5 + - - NX M0
49 47 F RCC, clear and granular cell type 8 + - - NX M0
50 55 F RCC, clear cell type 3 + - - NX M0
51                                Normal of No. 4
52                                Normal of No. 16
53                                Normal of No. 20
54                                Normal of No. 21
55                                Normal of No. 30
56                                Normal of No. 36
57                                Normal of No. 42
58                                Normal of No. 48
59                                Normal of No. 50
60                                Carbon particles
                   
#2 * lung metastasis              
#8 *: metastasis to contralateral kidney            
#17 *: perinephric fat involvement, **: bone metastasis            
#27 *: adrenal gland involvement, Gerota's fascia involvement            
#37 *: perinephric fat involvement            
#44 *: perinephric fat involvement            

General Information of the Tissue Array Slide :

Applications

  • Immunohistochemistry
  • In situ hybridization, RNA or DNA
  • Fluorescent in situ hybridization (FISH)
  • In situ PCR, RNA or DNA
  • TUNEL for apoptosis (Recommended procedures in www.tissue-array.com -> protocol)

Storage and stability

  • Individual slide is paraffin-coated and put in an air-tight pack with inert gas.
  • Tissue array slides are shipped in room temperature.
  • If the slides are stored in 4 degree, they are good up to one year.

How processed

  • Tissues were initially fixed with formalin except for some of the animal tissues.
  • Then, dehydrated with gradient ethanol; typically 1 hour each progressive steps; 70%, 90%, 95%, 99%, 100% x 3 times.
  • Cleared by xylene, three changes for 1 hour each.
  • Infiltrated with 60°C paraffin, three changes for 1 hour each
  • Microtoming in 4 µm thickness and put on silane coating slide from Muto Pure Chemicals (Japan)

Before use

  • Dry slides for 1 hour in a oven at 60 degree.
  • Dewax slides in xylene for 4 minutes x 5 times
  • Hydrate slides in 100%, 95% and 75% ethanol for 3 minutes x 2 times each.
  • Immerse slides in tap water for 5 minutes

Slide orientation

  • In most of the slides with 59 or 60 cores, the orientation is as below unless indicated otherwise. #60 location is usually filled with carbon for orientation.

Shaded area

1 2 3 4 5 6 7 8 9 10
11 12 13 14 15 16 17 18 19 20
21 22 23 24 25 26 27 28 29 30
31 32 33 34 35 36 37 38 39 40
41 42 43 44 45 46 47 48 49 50
51 52 53 54 55 56 57 58 59 60
Category Human tissue array
   Cat. No. CJ
   Product description Ovary cancer
   Data sheet CJ1
CJ1
  general_information
   No. of samples 59
   Text
Current version: CJ1 
Overy cancer: 59 cores

Price : 5 slide for 600 $

CJ1  Ovary cancer
         
  Age Sex Diagnosis SNOMED 
1 65 F serous papillary cystadenoma of borderline malignancy M84601
2 26 F mucinous cystic tumor of borderline malignancy M84701
3 35 F serous papillary cystadenoma of borderline malignancy M84601
4 65 F serous cyctadenocarcinoma M84603
5 48 F endometrioid carcinoma M83803
6 44 F granulosa cell tumor M86201
7 49 F endometrioid carcinoma M83803
8 67 F mucinous cystadenoma of borderline malignancy M84701
9 75 F serous cystadenofibroma M90140
10 50 F papillary serous cystadenocarcinoma , poorly differentiation M84603
11 44 F fibroma M88100
12 50 F papillary serous cystadenocarcinoma M84603
13 47 F endometrioid carcinoma M83803
14 38 F mixed Brenner tumor and mucinous cystadenoma M90000
15 58 F papillary serous cystadenocarcinoma M84603
16 70 F papillary serous cystadenocarcinoma M84603
17 65 F stroma ovarii M90900
18 79 F endometrioid adenoacanthofibroma M83810
19 57 F serous surface papillary carcinoma M84613
20 43 F papillary serous cystadenocarcinoma M84603
21 68 F undifferentiated carcinoma  M80203
22 50 F clear cell carcinoma M83103
23 23 F dysgerminoma M90603
24 51 F common epithelial carcinoma , poorly differentiation M80203
25 70 F malignant mullerian mixed tumor M89503
26 21 F dysgerminoma M90603
27 34 F fibrothecoma M86000
28 61 F papillary serous cystadenocarcinoma M84603
29 54 F Sertoli-Leydig cell tumor M86310
30 53 F fibrothecoma M86000
31 54 F fibrothecoma M86000
32 34 F papillary serous cystadenocarcinoma M84603
33 31 F dysgerminoma M90603
34 51 F papillary serous cystadenocarcinoma M84603
35 61 F granulosa-theca cell tumor M86211
36 24 F Sertoli-Leydig cell tumor M86310
37 27 F sclerosing stromal tumor M85901
38 41 F clear cell carcinoma M83103
39 56 F malignant mullerian mixed tumor M89503
40 41 F clear cell carcinoma M83103
41 27 F embrional carcinoma M90703
42 55 F granulosa cell tumor M86201
43 23 F dysgerminoma M90603
44 64 F papillary serous cystadenocarcinoma M84601
45 43 F metastatic adenocarcinoma ( most likely from breast ) M81406
46 48 F malignant lymphoma M95903
47 50 F adenocarcinoma from salpinx M81406
48 25 F fibrothecoma M86000
49 46 F metastatic undifferentiated carcinoma M80206
50 37 F metastatic signet ring carcinoma (Krukenberg tumor) M84906
51 55 F serous cystadenocarcinoma , moderately  differentiation M84603
52 55 F fibrothecoma M86000
53 45 F serous cystadenocarcinoma , moderately  differentiation M84603
54 37 F endometrioid carcinoma M83803
55 58 F fibrothecoma M86000
56 65 F adenocarcinoma , poorly differentiation M80203
57 39 F clear cell carcinoma M83103
58 70 F fibroma M88100
59 58 F clear cell carcinoma M83103
60 carbon

General Information of the Tissue Array Slide :

Applications

  • Immunohistochemistry
  • In situ hybridization, RNA or DNA
  • Fluorescent in situ hybridization (FISH)
  • In situ PCR, RNA or DNA
  • TUNEL for apoptosis (Recommended procedures in www.tissue-array.com -> protocol)

Storage and stability

  • Individual slide is paraffin-coated and put in an air-tight pack with inert gas.
  • Tissue array slides are shipped in room temperature.
  • If the slides are stored in 4 degree, they are good up to one year.

How processed

  • Tissues were initially fixed with formalin except for some of the animal tissues.
  • Then, dehydrated with gradient ethanol; typically 1 hour each progressive steps; 70%, 90%, 95%, 99%, 100% x 3 times.
  • Cleared by xylene, three changes for 1 hour each.
  • Infiltrated with 60°C paraffin, three changes for 1 hour each
  • Microtoming in 4 µm thickness and put on silane coating slide from Muto Pure Chemicals (Japan)

Before use

  • Dry slides for 1 hour in a oven at 60 degree.
  • Dewax slides in xylene for 4 minutes x 5 times
  • Hydrate slides in 100%, 95% and 75% ethanol for 3 minutes x 2 times each.
  • Immerse slides in tap water for 5 minutes

Slide orientation

  • In most of the slides with 59 or 60 cores, the orientation is as below unless indicated otherwise. #60 location is usually filled with carbon for orientation.

Shaded area

1 2 3 4 5 6 7 8 9 10
11 12 13 14 15 16 17 18 19 20
21 22 23 24 25 26 27 28 29 30
31 32 33 34 35 36 37 38 39 40
41 42 43 44 45 46 47 48 49 50
51 52 53 54 55 56 57 58 59 60
Category Human tissue array
   Cat. No. CH
   Product description larynx and pharynx cancer
   Data sheet CH1xls
CH1
    
  general_information
   No. of samples 60
   Text
Current version: CH1 
larynx or pharynx cancer: 60 cores

Price : 5 slide for 600 $

CH1   Human larynx and pharynx cancer
             
  Age Sex Location Diagnosis TNM Stage
1 43 M larynx, pyriform sinus  SCC*, moderately differentiated T4N2M0 ⅣA
2 55 M larynx, subglottic SCC, moderately differentiated T4N0M0 ⅣA
3 72 M larynx, supraglottic SCC, moderately differentiated T3N0M0
4 63 M esophagus SCC, basaloid type T4N0M0 ⅣA
5 67 M larynx, transglottic SCC, well differentiated T4N2bM0 ⅣA
6 63 M larynx, pyriform sinus SCC, moderately differentiated T4N2cM0 ⅣA
7 60 M larynx, supraglottic SCC, moderately differentiated T4N2cM0 ⅣA
8 61 M larynx, glottic SCC, moderately differentiated T4N0M0 ⅣA
9 66 M larynx, glottic SCC, moderately differentiated T4N0M0 ⅣA
10 56 M larynx, glottic SCC, well differentiated T1N0M0
11 62 M larynx, supraglottic SCC, moderately differentiated T3N2M0 ⅣA
12 56 M larynx, pyriform sinus  SCC, moderately differentiated T4N2bM0 ⅣA
13 54 M larynx, supraglottic SCC, well differentiated T3N0M0
14 48 M larynx, transglottic SCC, well differentiated T3N0M0
15 61 M larynx, supraglottic SCC, well differentiated T3N0M0
16 66 M soft tissue of neck SCC, well differentiated of hypopharynx T4N0M0
17 51 M larynx, supraglottic SCC, moderately differentiated T4N2cM0 ⅣA
18 46 M soft tissue, neck SCC of hypopharynx T2N3M0 ⅣB
19 52 M larynx, supraglottic SCC, moderately differentiated T2N0M0
20 52 F Nasal cavity undifferentiated carcinoma T4NxM0 ⅣA
21 64 M larynx, transglottic basaloid SCC T3N1M0
22 28 F lymph node undifferentiated carcinoma from nasopharynx T1N2cMx 0
23 63 M Nasopharynx undifferentiated carcinoma TxN2M1 ⅣC
24 77 M Neck undifferentiated carcinoma TxN2M0 ⅣA
25 51 M larynx, transglottic SCC, well differentiated T4N2M0 ⅣA
26 51 M hypopharynx SCC, moderately differentiated TxN1M0
27 59 M nasal cavity SCC, poorly differentiated T4N0M0 ⅣA
28 55 M larynx, subglottic SCC, moderately differentiated T3N0M0
29 60 M larynx, transglottic Larynx, SCC, well differentiated T4N0M0 ⅣA
30 70 M oropharynx undifferentiated carcinoma T1N2aM0 ⅣA
31 55 M hypopharynx squamous cell carcinoma, poorly differentiated T4N2bM0 ⅣA
32 62 M larynx, pyriform sinus SCC T3N0M0
33 48 M soft tissue, neck SCC from larynx T2N1M0
34 66 M larynx, supraglottic SCC, moderately differentiated T4N2bM0 ⅣA
35 58 M larynx, transglottic SCC, well differentiated T3N0M0
36 76 M larynx, supraglottic SCC, moderately differentiated T3N1M0
37 61 M larynx, supraglottic SCC, well differentiated T4N2bM0 ⅣA
38 66 M submandibular gland undifferentiated ca. with lymphoid stroma T3N2M0
39 54 M tonsil SCC, poorly differentiated T2N2bM0 ⅣA
40 61 M nose SCC, poorly differentiated T3N0M0
41 65 M larynx, glottic Larynx, SCC, moderately differentiated T4NxM1 ⅣC
42 54 M skin, neck undifferentiated carcinoma from nasopharynx T4N2aM0 ⅣA
43 82 F larynx, supraglottic SCC, moderately differentiated T3N1M0
44 56 M larynx, subglottic SCC T4N2bM0 ⅣA
45 75 M larynx, transglottic SCC, well differentiated T4N0M0 ⅣA
46 69 M larynx, glottic SCC, poorly differentiated T4N2bM0 ⅣA
47 43 M larynx, subglottic SCC, moderately differentiated T3N0M0
48 60 M larynx, glottic SCC T4N0M0 ⅣA
49 66 M larynx, supraglottic SCC, poorly differentiated T2N0M0
50 34 F breast medullary carcinoma TNM 0
51 58 M larynx, pyriform sinus SCC T3N2bM0 ⅣA
52 47 F maxilla undifferentiated carcinoma T1N0M0
53 65 M larynx, glottic SCC, well differentiated T4N2M0 ⅣA
54 78 M larynx, supraglottic SCC, moderately differentiated T4N1M0 ⅣA
55 69 M epiglottis basaloid SCC T2N0M0
56 60 M epiglottis SCC, moderately differentiated T2N3M0 ⅣB
57 46 F lymph node, neck undifferentiated ca., primary site unknown TNM 0
58 70 M larynx, glottic SCC, poorly differentiated T4N2M0 ⅣA
59 79 M larynx, supraglottic SCC, poorly differentiated T3N2bM0 ⅣA
60 52 M larynx, supraglottic SCC T3N1M0
             
*SCC: squamous cell carcinoma      
TNM and stage classification : larynx and pharynx cancer (AJCC 5th Edition)    

General Information of the Tissue Array Slide :

Applications

  • Immunohistochemistry
  • In situ hybridization, RNA or DNA
  • Fluorescent in situ hybridization (FISH)
  • In situ PCR, RNA or DNA
  • TUNEL for apoptosis (Recommended procedures in www.tissue-array.com -> protocol)

Storage and stability

  • Individual slide is paraffin-coated and put in an air-tight pack with inert gas.
  • Tissue array slides are shipped in room temperature.
  • If the slides are stored in 4 degree, they are good up to one year.

How processed

  • Tissues were initially fixed with formalin except for some of the animal tissues.
  • Then, dehydrated with gradient ethanol; typically 1 hour each progressive steps; 70%, 90%, 95%, 99%, 100% x 3 times.
  • Cleared by xylene, three changes for 1 hour each.
  • Infiltrated with 60°C paraffin, three changes for 1 hour each
  • Microtoming in 4 µm thickness and put on silane coating slide from Muto Pure Chemicals (Japan)

Before use

  • Dry slides for 1 hour in a oven at 60 degree.
  • Dewax slides in xylene for 4 minutes x 5 times
  • Hydrate slides in 100%, 95% and 75% ethanol for 3 minutes x 2 times each.
  • Immerse slides in tap water for 5 minutes

Slide orientation

  • In most of the slides with 59 or 60 cores, the orientation is as below unless indicated otherwise. #60 location is usually filled with carbon for orientation.

Shaded area

1 2 3 4 5 6 7 8 9 10
11 12 13 14 15 16 17 18 19 20
21 22 23 24 25 26 27 28 29 30
31 32 33 34 35 36 37 38 39 40
41 42 43 44 45 46 47 48 49 50
51 52 53 54 55 56 57 58 59 60
Category Human tissue array
   Cat. No. CDN
   Product description Normal colon and rectum tissue
   Data sheet CDN1
CDN1
  general_information
   No. of samples 59
   Text
current version: CDN1 
No. of normal cores: 59cores

Price : 5 slide for 600$

CDN1   Normal tissue of CD1
             
  Age Sex Histology Abnormal finding No. of CD1#  
101 60 F large bowel, mucosa . 1 .
102 58 F large bowel, mucosa . 2 .
103 51 M large bowel, mucosa . 3 .
104 38 F large bowel, mucosa . 4 .
105 56 M large bowel, mucosa . 5 .
106 46 F large bowel, mucosa . 6 .
107 61 M large bowel, mucosa . 7 .
108 40 F large bowel, mucosa . 8 .
109 36 F large bowel, mucosa . 9 .
110 68 M large bowel, mucosa . 10 .
111 62 F large bowel, mucosa . 11 .
112 65 M large bowel, mucosa . 12 .
113 65 M large bowel, mucosa . 13 .
114 72 F large bowel, mucosa . 14 .
115 63 M large bowel, mucosa . 15 .
116 73 F large bowel, mucosa . 16 .
117 60 M large bowel, mucosa . 17 .
118 65 F large bowel, mucosa . 18 .
119 57 M large bowel, mucosa . 19 .
120 58 M large bowel, mucosa . 20 .
121 56 M large bowel, mucosa . 21 .
122 57 M large bowel, mucosa . 22 .
123 56 M large bowel, mucosa . 23 .
124 36 M large bowel, mucosa . 24 .
125 65 F large bowel, mucosa . 25 .
126 62 M large bowel, mucosa . 26 .
127 57 F large bowel, mucosa . 27 .
128 78 M large bowel, mucosa . 28 .
129 45 M large bowel, mucosa . 29 .
130 65 M large bowel, mucosa . 30 .
131 61 M large bowel, mucosa . 31 .
132 52 M large bowel, mucosa . 32 .
133 52 F large bowel, mucosa . 33 .
134 47 F large bowel, mucosa . 34 .
135 63 F large bowel, mucosa . 35 .
136 53 M large bowel, mucosa . 36 .
137 53 F large bowel, mucosa . 37 .
138 64 M large bowel, mucosa . 38 .
139 59 M large bowel, mucosa . 39 .
140 57 M large bowel, mucosa . 40 .
141 46 F large bowel, mucosa . 41 .
142 59 M large bowel, mucosa . 42 .
143 35 F large bowel, mucosa . 43 .
144 42 M large bowel, mucosa . 44 .
145 49 F large bowel, mucosa . 45 .
146 76 M large bowel, mucosa . 46 .
147 74 M large bowel, mucosa . 47 .
148 60 F large bowel, mucosa . 48 .
149 62 M large bowel, mucosa . 49 .
150 62 M large bowel, mucosa . 50 .
151 57 M large bowel, mucosa . 51 .
152 56 F large bowel, mucosa . 52 .
153 75 F large bowel, mucosa . 53 .
154 58 M large bowel, mucosa . 54 .
155 56 M large bowel, mucosa . 55 .
156 35 M large bowel, mucosa . 56 .
157 34 M large bowel, mucosa . 57 .
158 60 M large bowel, mucosa . 58 .
159 70 M large bowel, mucosa . 59 .
160 Carbon          
             
#: The cancer tissue in CD1 array of this column is from the identical patient.    

General Information of the Tissue Array Slide :

Applications

  • Immunohistochemistry
  • In situ hybridization, RNA or DNA
  • Fluorescent in situ hybridization (FISH)
  • In situ PCR, RNA or DNA
  • TUNEL for apoptosis (Recommended procedures in www.tissue-array.com -> protocol)

Storage and stability

  • Individual slide is paraffin-coated and put in an air-tight pack with inert gas.
  • Tissue array slides are shipped in room temperature.
  • If the slides are stored in 4 degree, they are good up to one year.

How processed

  • Tissues were initially fixed with formalin except for some of the animal tissues.
  • Then, dehydrated with gradient ethanol; typically 1 hour each progressive steps; 70%, 90%, 95%, 99%, 100% x 3 times.
  • Cleared by xylene, three changes for 1 hour each.
  • Infiltrated with 60°C paraffin, three changes for 1 hour each
  • Microtoming in 4 µm thickness and put on silane coating slide from Muto Pure Chemicals (Japan)

Before use

  • Dry slides for 1 hour in a oven at 60 degree.
  • Dewax slides in xylene for 4 minutes x 5 times
  • Hydrate slides in 100%, 95% and 75% ethanol for 3 minutes x 2 times each.
  • Immerse slides in tap water for 5 minutes

Slide orientation

  • In most of the slides with 59 or 60 cores, the orientation is as below unless indicated otherwise. #60 location is usually filled with carbon for orientation.

Shaded area

1 2 3 4 5 6 7 8 9 10
11 12 13 14 15 16 17 18 19 20
21 22 23 24 25 26 27 28 29 30
31 32 33 34 35 36 37 38 39 40
41 42 43 44 45 46 47 48 49 50
51 52 53 54 55 56 57 58 59 60
Category Human tissue array
   Cat. No. CDA
   Product description colorectal: cancer-metastasis-normal
   Data sheet CDA2
CDA2
     
  general_information
   No. of samples 59
   Text
current version : CDA2 
cancer :40 cores 
metastatic cancer :10 cores 
normal :9 cores

Price : 5slide for 600 $

CDA2  Human, colon and rectal cancer
               
  Age  Sex Site Pathology TNM Stage Months*
1 40 F sigmoid adenocarcinoma, W/D T3N2M0 ⅢC .
2 65 F cecum Mucinous adenocarcinoma T3N2M0 ⅢC .
3 56 M ascending adenocarcinoma, M/D T4N1M0 ⅢB .
4 65 F sigmoid adenocarcinoma, W/D T3N0M0 ⅡA .
5 62 M ascending adenocarcinoma, M/D T3N0M0 ⅡA .
6 57 F sigmoid adenocarcinoma, W/D T3N1M0 ⅢB .
7 78 M sigmoid adenocarcinoma, W/D T3N1M0 ⅢB .
8 45 M rectum adenocarcinoma, W/D T3N1M0 ⅢB .
9 65 M ascending adenocarcinoma, W/D T3N1M0 ⅢB .
10 61 M transverse Mucinous adenocarcinoma T3N0M0 ⅡA .
11 52 M rectum adenocarcinoma, M/D T3N0M1 .
12 52 F sigmoid adenocarcinoma, M/D T2N2M0 ⅢC .
13 47 F cecum adenocarcinoma, M/D T3N0M0 ⅡA .
14 63 F descending adenocarcinoma, M/D T3N1M0 ⅢB .
15 53 M cecum adenocarcinoma, M/D T3N1M0 ⅢB .
16 53 F transverse adenocarcinoma, W/D T3N0M0 ⅡA .
17 64 M sigmoid adenocarcinoma, M/D T3N1M0 ⅢB .
18 59 M sigmoid adenocarcinoma, M/D T4N0M0 ⅡB .
19 57 M ascending adenocarcinoma, M/D T4N0M0 ⅡB .
20 59 M ascending adenocarcinoma, M/D T3N0M0 ⅡA .
21 35 F ascending Mucinous adenocarcinoma T3N0M0 ⅡA .
22 49 F ascending adenocarcinoma, M/D T3N2M0 ⅢB .
23 76 M sigmoid adenocarcinoma, M/D T3N1M1 .
24 74 M ascending adenocarcinoma, M/D T3N0M0 ⅡA .
25 60 F rectum adenocarcinoma, M/D T4N0M0 ⅡB .
26 62 M sigmoid adenocarcinoma, M/D T3N0M0 ⅡA .
27 57 M sigmoid adenocarcinoma, M/D T3N0M0 ⅡA .
28 56 F sigmoid adenocarcinoma, M/D T3N2M1 .
29 75 F rectum adenocarcinoma, W/D T3N1M0 ⅢB .
30 58 M rectum adenocarcinoma, M/D T3N0MX ⅡA .
31 62 M rectum adenocarcinoma, M/D T4N1M0 ⅢB .
32 65 F cecum Mucinous adenocarcinoma T3N2M0 ⅢC .
33 36 M transverse adenocarcinoma, M/D T3N2M0 ⅢC .
34 . F descending adenocarcinoma, W/D T4N1M1 .
35 46 F ascending adenocarcinoma, P/D T3N2MX ⅢC .
36 42 M transverse adenocarcinoma, M/D T3N2M0 ⅢC .
37 62 M sigmoid adenocarcinoma, M/D T3N2M1 .
38 41 F sigmoid adenocarcinoma, W/D T4N2M1 .
39 51 M rectum adenocarcinoma, M/D T4N2M0 ⅢC .
40 47 F sigmoid adenocarcinoma, M/D T4N1M1 .
41 66 M lung metastatic adenocarcinoma from #31 . . 42
42 65 F lymph node metastatic carcinoma from #32 . . 0
43 36 M lymph node metastatic carcinoma from #33 . . 0
44 . F ovary metastatic adenocarcinoma from #34 . . 0
45 46 F lymph node metastatic carcinoma from #35 . . 0
46 42 M lymph node metastatic carcinoma from #36 . . 0
47 62 M lymph node metastatic carcinoma from #37 . . 0
48 41 F ovary metastatic adenocarcinoma from #38 . . 0
49 52 M lung metastatic adenocarcinoma from #39 . . 17
50 47 F ovary metastatic adenocarcinoma from #40 . . 0
51 40 F sigmoid normal colon (adjacent to cancer, match of #1) . . .
52 68 M sigmoid normal colon (adjacent to cancer, match of #2) . . .
53 45 M rectum normal colon (adjacent to cancer, match of #8) . . .
54 62 M sigmoid normal colon (adjacent to cancer, match of #26) . . .
55 42 M transverse normal colon (adjacent to cancer, match of #36) . . .
56 49 F ascending normal colon (apart from cancer, match of #22) . . .
57 76 M sigmoid normal colon (apart from cancer, match of #23) . . .
58 36 M transverse normal colon (apart from cancer, match of #33) . . .
59 62 M sigmoid normal colon (apart from cancer, match of #37) . . .
60 carbon            
               
*: interval between primary and metastatic cancer        
   W/D, well differentiated; M/D, moderately differentiated; P/D, poorly differentiated      
TNM Classification : Colon and Rectum carcinoma (AJCC 6th Edition)      

General Information of the Tissue Array Slide :

Applications

  • Immunohistochemistry
  • In situ hybridization, RNA or DNA
  • Fluorescent in situ hybridization (FISH)
  • In situ PCR, RNA or DNA
  • TUNEL for apoptosis (Recommended procedures in www.tissue-array.com -> protocol)

Storage and stability

  • Individual slide is paraffin-coated and put in an air-tight pack with inert gas.
  • Tissue array slides are shipped in room temperature.
  • If the slides are stored in 4 degree, they are good up to one year.

How processed

  • Tissues were initially fixed with formalin except for some of the animal tissues.
  • Then, dehydrated with gradient ethanol; typically 1 hour each progressive steps; 70%, 90%, 95%, 99%, 100% x 3 times.
  • Cleared by xylene, three changes for 1 hour each.
  • Infiltrated with 60°C paraffin, three changes for 1 hour each
  • Microtoming in 4 µm thickness and put on silane coating slide from Muto Pure Chemicals (Japan)

Before use

  • Dry slides for 1 hour in a oven at 60 degree.
  • Dewax slides in xylene for 4 minutes x 5 times
  • Hydrate slides in 100%, 95% and 75% ethanol for 3 minutes x 2 times each.
  • Immerse slides in tap water for 5 minutes

Slide orientation

  • In most of the slides with 59 or 60 cores, the orientation is as below unless indicated otherwise. #60 location is usually filled with carbon for orientation.

Shaded area

1 2 3 4 5 6 7 8 9 10
11 12 13 14 15 16 17 18 19 20
21 22 23 24 25 26 27 28 29 30
31 32 33 34 35 36 37 38 39 40
41 42 43 44 45 46 47 48 49 50
51 52 53 54 55 56 57 58 59 60
Category Human tissue array
   Cat. No. CD
   Product description colon and rectum cancer
   Data sheet CD1
CD1
     
  general_information
   No. of samples 59
   Text
Current version: CD1 
Colorectal cancer: 59 cores

Price : 5 slide for 600 $

CD1  Human, colon and rectal cancer
               
  Age  Sex site Pathology TNM Stage No. of 
CDN1#
1 60 F ascending  adenocarcinoma, M/D T3N0M0 101
2 58 F rectum adenocarcinoma, M/D T3N1MX 102
3 51 M transverse adenocarcinoma, P/D T3N0M0 103
4 38 F transverse adenocarcinoma, M/D T3N0M0 104
5 56 M sigmoid adenocarcinoma, W/D T3N2M0 105
6 46 F cecum adenocarcinoma, M/D T2N1M0 106
7 61 M cecum adenocarcinoma, mucinous T3N0M0 107
8 40 F sigmoid adenocarcinoma, W/D T3N2M0 108
9 36 F descending adenocarcinoma, M/D T3N0M0 109
10 68 M sigmoid adenocarcinoma, M/D T3N1M0 110
11 62 F sigmoid adenocarcinoma, M/D T3N0M0 111
12 65 M ascending adenocarcinoma, W/D T3N2M0 112
13 65 M sigmoid adenocarcinoma, M/D T3N0M0 113
14 72 F sigmoid adenocarcinoma, W/D T3N1M0 114
15 63 M ascending adenocarcinoma, W/D T3N0M0 115
16 73 F transverse adenocarcinoma, M/D T3N0M0 116
17 60 M sigmoid adenocarcinoma, M/D T3N0M0 117
18 65 F cecum adenocarcinoma, mucinous T3N2M0 118
19 57 M sigmoid adenocarcinoma, M/D T3N0M1 119
20 58 M cecum adenocarcinoma, M/D T3N0M0 120
21 56 M ascending adenocarcinoma, mucinous T3N0M0 121
22 57 M sigmoid adenocarcinoma, M/D T3N0M0 122
23 56 M ascending adenocarcinoma, M/D T4N1M0 123
24 36 M transverse adenocarcinoma, M/D T3N2M0 124
25 65 F sigmoid adenocarcinoma, W/D T3N0M0 125
26 62 M ascending adenocarcinoma, M/D T3N0M0 126
27 57 F sigmoid adenocarcinoma, W/D T3N1M0 127
28 78 M sigmoid adenocarcinoma, W/D T3N1M0 128
29 45 M rectum adenocarcinoma, W/D T3N1M0 129
30 65 M ascending adenocarcinoma, W/D T3N1M0 130
31 61 M transverse adenocarcinoma, mucinous T3N0M0 131
32 52 M rectum adenocarcinoma, M/D T3N0M1 132
33 52 F sigmoid adenocarcinoma, M/D T2N2M0 133
34 47 F cecum adenocarcinoma, M/D T3N0M0 134
35 63 F descending adenocarcinoma, M/D T3N1M0 135
36 53 M cecum adenocarcinoma, M/D T3N1M0 136
37 53 F transverse adenocarcinoma, W/D T3N0M0 137
38 64 M sigmoid adenocarcinoma, M/D T3N1M0 138
39 59 M sigmoid adenocarcinoma, M/D T4N0M0 139
40 57 M ascending adenocarcinoma, M/D T4N0M0 140
41 46 F ascending adenocarcinoma, P/D T3N2MX 141
42 59 M ascending adenocarcinoma, M/D T3N0M0 142
43 35 F ascending adenocarcinoma, mucinous T3N0M0 143
44 42 M transverse adenocarcinoma, M/D T3N2M0 144
45 49 F ascending adenocarcinoma, M/D T3N2M0 145
46 76 M sigmoid adenocarcinoma, M/D T3N1M1 146
47 74 M ascending adenocarcinoma, M/D T3N0M0 147
48 60 F rectum adenocarcinoma, M/D T4N0M0 148
49 62 M sigmoid adenocarcinoma, M/D T3N2M1 149
50 62 M sigmoid adenocarcinoma, M/D T3N0M0 150
51 57 M sigmoid adenocarcinoma, M/D T3N0M0 151
52 56 F sigmoid adenocarcinoma, M/D T3N2M1 152
53 75 F rectum adenocarcinoma, W/D T3N1M0 153
54 58 M rectum adenocarcinoma, M/D T3N0MX 154
55 56 M ascending adenocarcinoma, M/D T3N1M0 155
56 35 M rectum adenocarcinoma, M/D T2N1M0 156
57 34 M ascending adenocarcinoma, M/D T3N1M0 157
58 60 M transverse adenocarcinoma, W/D T3N0M0 158
59 70 M descending adenocarcinoma, M/D T3N0M0 159
60 carbon            
               
*WHO classification     W/D: well differentiated      
        M/D: moderately differentiated      
        P/D: poorly differentiated      
#: The normal tissue in CDN1 array of corresponding number is from the identical patient.      
TNM classification : colon and rectum carcinoma (AJCC 5 th Edition)      

General Information of the Tissue Array Slide :

Applications

  • Immunohistochemistry
  • In situ hybridization, RNA or DNA
  • Fluorescent in situ hybridization (FISH)
  • In situ PCR, RNA or DNA
  • TUNEL for apoptosis (Recommended procedures in www.tissue-array.com -> protocol)

Storage and stability

  • Individual slide is paraffin-coated and put in an air-tight pack with inert gas.
  • Tissue array slides are shipped in room temperature.
  • If the slides are stored in 4 degree, they are good up to one year.

How processed

  • Tissues were initially fixed with formalin except for some of the animal tissues.
  • Then, dehydrated with gradient ethanol; typically 1 hour each progressive steps; 70%, 90%, 95%, 99%, 100% x 3 times.
  • Cleared by xylene, three changes for 1 hour each.
  • Infiltrated with 60°C paraffin, three changes for 1 hour each
  • Microtoming in 4 µm thickness and put on silane coating slide from Muto Pure Chemicals (Japan)

Before use

  • Dry slides for 1 hour in a oven at 60 degree.
  • Dewax slides in xylene for 4 minutes x 5 times
  • Hydrate slides in 100%, 95% and 75% ethanol for 3 minutes x 2 times each.
  • Immerse slides in tap water for 5 minutes

Slide orientation

  • In most of the slides with 59 or 60 cores, the orientation is as below unless indicated otherwise. #60 location is usually filled with carbon for orientation.

Shaded area

1 2 3 4 5 6 7 8 9 10
11 12 13 14 15 16 17 18 19 20
21 22 23 24 25 26 27 28 29 30
31 32 33 34 35 36 37 38 39 40
41 42 43 44 45 46 47 48 49 50
51 52 53 54 55 56 57 58 59 60
Page 2 of 3

Tags